Related Experiment Video
Updated: Dec 20, 2025
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Rothia mucilaginosa Infections in Pediatric Cancer Patients
Rachel B Getzenberg1, Diego R Hijano2, Hana Hakim2
1University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Abstract:
We performed a retrospective study to determine the epidemiology of Rothia mucilaginosa infections among pediatric cancer patients. Over 20 years, 37 cases were identified; 27% developed complications, but there was no infection-related mortality. All cases were successfully treated with vancomycin.
Insights
Rothia mucilaginosa infections are rare in pediatric cancer patients, with no reported deaths over 20 years. Vancomycin effectively treated all identified cases, with few complications.
Area of Science:
- Infectious Diseases
- Pediatric Oncology
Background:
- Rothia mucilaginosa is an opportunistic pathogen.
- Infections in immunocompromised hosts require careful monitoring.
Purpose of the Study:
- To investigate the epidemiology of Rothia mucilaginosa infections in pediatric cancer patients.
- To assess the outcomes and treatment of these infections.
Main Methods:
- Retrospective study design.
- Analysis of 37 cases over a 20-year period.
- Review of patient data, complications, and treatment regimens.
Main Results:
- 37 cases of Rothia mucilaginosa infection identified over two decades.
- 27% of patients experienced complications.
- No infection-related mortality was observed.
- All patients were successfully treated with vancomycin.
Conclusions:
- Rothia mucilaginosa infections in pediatric cancer patients are uncommon.
- These infections, while potentially causing complications, are manageable and not typically fatal.
- Vancomycin is an effective treatment for Rothia mucilaginosa infections in this population.
